异基因造血干细胞移植联合伊马替尼治疗Ph~+急性淋巴细胞白血病

为了探讨异基因造血干细胞移植(allo-HSCT)联合伊马替尼治疗Ph+急性淋巴细胞白血病(Philadelphiachromosome positive acute lymphoblastic leukemia,Ph+ALL)的疗效。对我院2007-2008年Ph+ALL患者3例所进行的allo-HSCT联合伊马替尼治疗效果进行了小结。3例Ph+ALL中1例接受同胞全相合移植,另2例为单倍体相合移植,移植前均处于完全缓解状态。3例患者在移植前后不同时间接受不同疗程的伊马替尼治疗,同时应用RT-PCR方法监测bcr/abl融合基因转录水平。随访日期至2009年10月21日。结果表明:3例患者均成功植入,未出现严重移植相关并发症;移植后bcr/abl融合基因处于低转录水平并逐渐转阴。结论:异基因造血干细胞移植联合伊马替尼是Ph+ALL有效的治疗方法。

Allogeneic Hematopoietie Stem Cell Transplantation Combined with Imatinib for Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

The study was purposed to explore the efficacy of allogeneic hematopoietic stem cell transplantation(allo-HSCT) combined with Imatinib for treatment of Philadelphia chromosome positive acute lymphoblastic leukemia(Ph+ALL) patients.From 2007 to 2008,3 patients with Ph+ ALL were treated with allogeneic hematopoietic stem cell transplantation and Imatinib,and the follow-up ended at Oct 21st 2009.1 patient received HSCT from matched sibling donor and 2 patients from haploidentical related donors.All 3 patients ...